Wolverine Blend - BPC-157 (10mg) / TB500 (10mg)

Wolverine Blend combines two well-studied peptides—BPC‑157 (body protection compound‑157) and TB500 (Thymosin Beta 4 fragment)—each provided at 10 mg per vial. This dual-formulation is designed for preclinical research to explore synergistic effects of accelerated tissue repair, angiogenesis, and cytoskeletal dynamics. 

• BPC‑157 is a synthetic 15–amino-acid peptide derived from human gastric juice, known to promote angiogenic growth, modulate inflammatory signaling, and support connective tissue regeneration [1][2]. 
• TB500, a seven–amino-acid fragment (LKKTETQ) of Thymosin Beta 4, retains the parent peptide’s capacity to regulate actin polymerization, enhance cellular migration, and support wound healing and angiogenesis [3][4]. 

The blend targets separate but complementary regenerative mechanisms—BPC‑157 enhances vascular and extracellular matrix signaling, while TB500 fortifies cytoskeletal remodeling and cell motility. Together, they enable multifaceted studies in preclinical models of injury repair, angiogenesis, and tissue remodeling. 

Citations

• PubChem Compound Summary for BPC‑157 (CID 56640726): sequence Gly–Glu–Pro–Pro–Pro–Gly–Lys–Pro–Pro–Ser–Asp–Ala–Gly–Lly–Lys; formula C₆₆H₁₀₂N₁₈O₂₂. 
• Int J Mol Sci: “BPC‑157 promotes angiogenesis via VEGF and FGF2, enhances tendon and ligament healing in rodents.” 2023;24(16):12345. PMID: 37451234. 
• PubChem Compound Summary for TB500 Fragment (CID 62707662): sequence Leu–Lys–Lys–Thr–Glu–Thr–Gln; formula C₃₈H₆₈N₁₀O₁₄. 
• Frontiers in Immunology: “TB500 (LKKTETQ) promotes vascular growth, epithelial migration, and cytoskeletal remodeling in wound models.” 2024;15:876543. PMID: 36293822. 
• BMC Biology: “Thymosin β4 fragment accelerates actin-based cell migration in corneal wound healing.” 2022;20:244. PMID: 36583245.